Immunicon Corporation (IMMC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunicon Corporation (IMMC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: tnsaf	9/26/2006 6:00:36 PM
	of 12

Immunicon Achieves Endpoints in its Pivotal Clinical Trial in Metastatic Colorectal Cancer HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company met the primary and secondary endpoints associated with its pivotal clinical trial in metastatic colorectal cancer. The primary endpoint was that the number of circulating tumor cells (CTCs) 3-5 weeks after the initiation of therapy would agree with a patient’s response to therapy as determined by imaging 6-12 weeks after initiation of therapy. The secondary endpoint was that the number of CTCs prior to and after the initiation of therapy would predict the clinical end points of progression-free survival and overall survival. The prospective, multi-center trial was designed for longitudinal enumeration of CTCs in patients with metastatic colorectal carcinomas measurable by imaging. A total of 481 patients were enrolled into the trial between February 2004 and February 2006, from a total of 55 sites in the United States and Europe. Imaging studies were performed prior to the initiation of therapy and at subsequent intervals of approximately 6-12 weeks. CTCs were measured at baseline, 1-2 and 3-5 weeks after the initiation of therapy, and at the time of all subsequent imaging studies (approximately every 6-12 weeks) using CellTracks® technology. Patients remained on the study and provided blood for up to 12 months or until documented evidence of disease progression and/or death. Leon Terstappen, MD, PhD, senior vice president and chief scientific officer of Immunicon commented, “We are pleased that the data in colorectal cancer are consistent with those in breast cancer and broadens the clinical utility of our products. We expect to submit the data to the FDA and for scientific presentations and publications by the end of this year.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext